Bonesupport Holding AB (publ) (BONEX) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Bonesupport Holding Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:06.207 basically driven by continued adoption and a clear pickup in trauma. 00:00:06.207 -- 00:00:11.895 If you look at some of the highlights in the quarter, at the AAOS 00:00:11.895 -- 00:00:17.123 meeting, the American Academy of Orthopedic Surgeons, that meeting was held earlier 00:00:17.123 -- 00:00:23.392 this year, and bone support hosted a well-attended satellite symposium 00:00:23.392 -- 00:00:28.720 focused on bone infection, featuring a European professor with 00:00:28.720 -- 00:00:32.225 deep expertise in trauma-induced 00:00:32.225 -- 00:00:34.203 bone infections. 00:00:34.203 -- 00:00:39.790 In addition, there were several trauma patient cases presentations 00:00:39.790 -- 00:00:43.394 from prominent U.S. trauma surgeons. 00:00:43.394 -- 00:00:49.121 Their real-world cases showed excellent results, mirroring the 00:00:49.121 -- 00:00:53.626 positive patient outcome seen in large-scale 00:00:53.626 -- 00:00:58.892 published clinical studies from, among others, Manchester University 00:00:58.892 -- 00:01:00.892 Hospital. 00:01:01.051 -- 00:01:06.466 We're seeing a strong interest among trauma surgeons, especially those 00:01:06.466 -- 00:01:11.801 dealing with severe injuries from, in example, traffic accidents 00:01:11.801 -- 00:01:17.223 where infection risk is high. Many of these surgeons have not previously 00:01:17.223 -- 00:01:22.253 used any local antibiotics, mainly due to the lack of FDA 00:01:22.253 -- 00:01:24.297 approved options. 00:01:24.297 -- 00:01:29.728 Saruman G is now filling that gap and expanding their infection 00:01:29.728 -- 00:01:34.674 prevention toolkit for a large part of the market. 00:01:34.835 -- 00:01:40.220 As mentioned earlier, Cerament V market authorization request was submitted 00:01:40.22...